A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2016
At a glance
- Drugs RG 4733 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 19 Jul 2016 Status changed from active, no longer recruiting to discontinued as it was administratively complete.
- 07 May 2013 Status changed from discontinued to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 May 2013 Planned number of patients changed from 50 to 25 as reported by ClinicalTrials.gov.